<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly</h2>
    <div class="badge">2025-09-15T12:44:22+00:00</div>
    <ul>
      <li>Sep 15 - Novo Nordisk (NYSE:NVO) reported that a higher semaglutide dose helped patients lose more weight in two late-stage trials, and its Copenhagen-listed shares rose about 1.5%.</li>
<li>The trials tested a 7.2 mg dose, three times the approved 2.4 mg, and measured weight change over 72 weeks.</li>
<li>Eli Lilly (NYSE:LLY) posted stronger headline results with tirzepatide, achieving up to 22.5 percent weight loss at its top dose, keeping competition tight.Observers said the incremental gains for semaglutide matter, esp</li>
<li>This article first appeared on GuruFocus.</li>
<li>In the larger study, participants on 7.2 mg lost an average of 19 percent of body weight, compared with about 16 percent on 2.4 mg and 4 percent on placebo.</li>
<li>Novo has faced setbacks in the U.S., including market share losses and a roughly 60 percent share decline over the past year as it trims its global workforce.</li>
<li>The data may strengthen Novo&#x27;s case for higher-dose strategies if regulators and payers accept the approach.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly\n• Sep 15 - Novo Nordisk (NYSE:NVO) reported that a higher semaglutide dose helped patients lose more weight in two late-stage trials, and its Copenhagen-listed shares rose about 1.5%.\n• The trials tested a 7.2 mg dose, three times the approved 2.4 mg, and measured weight change over 72 weeks.\n• Eli Lilly (NYSE:LLY) posted stronger headline results with tirzepatide, achieving up to 22.5 percent weight loss at its top dose, keeping competition tight.Observers said the incremental gains for semaglutide matter, esp\n• This article first appeared on GuruFocus.\n• In the larger study, participants on 7.2 mg lost an average of 19 percent of body weight, compared with about 16 percent on 2.4 mg and 4 percent on placebo.\n• Novo has faced setbacks in the U.S., including market share losses and a roughly 60 percent share decline over the past year as it trims its global workforce.\n• The data may strengthen Novo&#x27;s case for higher-dose strategies if regulators and payers accept the approach." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/novo-nordisk-shares-rise-obesity-124422607.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>